News
PCVX
85.78
-0.15%
-0.13
Carillon Eagle Small Cap Growth Fund Q3 2024 Commentary
Seeking Alpha · 2d ago
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
Barchart · 4d ago
Weekly Report: what happened at PCVX last week (1216-1220)?
Weekly Report · 4d ago
Vaxcyte’s Promising Pipeline and Strategic Positioning: A Buy Recommendation Amidst Market Challenges
TipRanks · 6d ago
Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset
Seeking Alpha · 6d ago
Vaxcyte Price Target Announced at $135.00/Share by Goldman Sachs
Dow Jones · 12/20 13:00
Goldman Sachs Initiates Coverage On Vaxcyte with Buy Rating, Announces Price Target of $135
Benzinga · 12/20 12:51
Vaxcyte initiated with a Buy at Goldman Sachs
TipRanks · 12/20 10:20
(PCVX) - Analyzing Vaxcyte's Short Interest
Benzinga · 12/16 15:30
Pioneer Select Mid Cap Growth Fund Q3 2024 Performance And Market Commentary
Seeking Alpha · 12/16 14:11
Weekly Report: what happened at PCVX last week (1209-1213)?
Weekly Report · 12/16 09:22
Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy”
Barchart · 12/11 12:47
Insider Sale: CHIEF EXECUTIVE OFFICER of $PCVX (PCVX) Sells 222 Shares
Barchart · 12/11 01:22
Insider Sale: SVP of $PCVX (PCVX) Sells 1,435 Shares
Barchart · 12/10 03:46
Weekly Report: what happened at PCVX last week (1202-1206)?
Weekly Report · 12/09 09:21
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Simply Wall St · 12/08 13:14
Vanguard Russell 2000 ETF Experiences Big Inflow
NASDAQ · 12/06 16:03
Vaxcyte: Promising Developments and Strategic Advancements Boost Confidence in Stock Potential
TipRanks · 12/06 05:56
Harbor Small Cap Growth Fund Q3 2024 Commentary
Seeking Alpha · 12/05 14:45
Vaxcyte Initiates Phase 2 Study for VAX-31 Pneumococcal Vaccine in Infants, Anticipates Topline Data in 2026
Barchart · 12/03 17:20
More
Webull provides a variety of real-time PCVX stock news. You can receive the latest news about Vaxcyte, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.